steroidmetabolizing

Steroid-metabolizing refers to the biochemical processes by which steroid hormones and related lipids are chemically modified to alter activity and promote elimination. The liver is the primary site, with contributions from the intestine, kidney, and, for locally produced steroids, adrenal and gonadal tissues. Metabolism generally proceeds in two phases: Phase I functionalization and Phase II conjugation.

Phase I reactions introduce or expose polar groups through oxidation, reduction, or hydrolysis, often catalyzed by cytochrome P450 enzymes (CYPs). CYP3A4 is a major contributor in hepatic steroid metabolism; others such as CYP2D6, CYP2C9, and CYP2C19 participate in specific substrates. Aromatase (CYP19) catalyzes the conversion of androgens to estrogens in peripheral tissues. Phase II reactions attach conjugates to increase water solubility; the most important are glucuronidation by UDP-glucuronosyltransferases (UGTs) and sulfation by sulfotransferases (SULTs). Acetylation, glutathione conjugation, and other conjugation pathways also occur for certain steroids or reactive intermediates.

The products of metabolism are typically more polar and are excreted in urine or bile, with enterohepatic recirculation possible for some glucuronide or sulfate conjugates. Metabolic efficiency varies with tissue distribution, genetic polymorphisms, age, disease, and drug interactions. Clinically, steroid metabolism influences hormonal activity, drug clearance, and susceptibility to adverse effects. Patients with liver impairment or those taking enzyme-inducing or -inhibiting drugs may exhibit altered steroid pharmacokinetics.